Luijten, J. C. H. B. M.
Vissers, P. A. J.
Brom, L.
de Bièvre, M.
Buijsen, J.
Rozema, T.
Mohammad, N. Haj
van Duijvendijk, P.
Kouwenhoven, E. A.
Eshuis, W. J.
Rosman, C.
Siersema, P. D.
van Laarhoven, H. W. M.
Verhoeven, R. H. A.
Nieuwenhuijzen, G. A. P.
Westerman, M. J.
Funding for this research was provided by:
KWF Kankerbestrijding (Project No. 10895, Project No. 10895)
Article History
Received: 1 November 2021
Accepted: 17 March 2022
First Online: 20 April 2022
Declarations
:
: The Medical Research Ethics Committees of the Netherlands confirmed that ethical approval was not required for this study (W.18.166). The participating hospitals approved this study. Written informed consent was obtained from all the participants prior to the interviews.
: Not applicable.
: PS: Research support or funding: EndoStim, Pentax, Norgine, Motus GI and The Enose company Advisory Board: Motus GIE.HvL: Consultant or advisory role: BMS, Lilly, MSD, Nordic Pharma, Servier, Research funding and/or medication supply: Bayer, BMS, Celgene, Janssen, Lilly, Nordic Pharma, Philips, Roche, Servier.RV: received research grants from Roche and Bristol-Myers Squibb.For the remaining authors no conflicts of interest were declared.